Bicycle Therapeutics plc (BCYC) News
Follow Bicycle Therapeutics plc (BCYC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bicycle Therapeutics Reports Quarterly Results for Period Ended September 30
EQUITY | Oct 29, 2026, 07:49 PM UTC
M
Bicycle Therapeutics Reports Lower Q3 2026 Net Loss
EQUITY | Oct 29, 2026, 11:21 AM UTC
M
Bicycle Therapeutics Reports Third-Quarter 2026 Results and FDA Orphan Drug Designation
Bicycle Therapeutics said nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer. The headline also reports third-quarter 2026 financial results, but the supplied body is truncated and provides n
EQUITY | Oct 29, 2026, 11:04 AM UTC
L
BCYC Bicycle Therapeutics RESULTS: Q2, Q2 operating incom $-54.559M, Q2 basic EPS $-0.72, Q2 Net Income $-50.333M, Q2 operating expenses $55
BCYC Bicycle Therapeutics RESULTS: Q2, Q2 operating incom $-54.559M, Q2 basic EPS $-0.72, Q2 Net Income $-50.333M, Q2 operating expenses $55.188M, Q2 pretax profit $-50.243M
EARNINGS | Jul 30, 2026, 11:02 AM UTC
L
BCYC - Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
BCYC - Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 11:02 AM UTC